Pathology & Oncology Research

, Volume 25, Issue 3, pp 1135–1142 | Cite as

Assessment of Gastritis and Gastric Cancer Risk in the Chilean Population Using the OLGA System

  • Enrique BellolioEmail author
  • Ismael RiquelmeEmail author
  • Angela L. Riffo-Campos
  • Carlos Rueda
  • Catterina Ferreccio
  • Miguel Villaseca
  • Priscilla Brebi
  • Sergio Muñoz
  • Juan Carlos Araya
Original Article


Gastric cancer (GC) is the first cancer-related cause of death in Chile; however, no plan for GC early detection has been implemented in this country. The OLGA system characterizes gastritis from stages 0 to IV according to the risk of developing GC based on H. pylori infection, atrophy, metaplasia and GC. In this study, the performance of the OLGA system was evaluated in 485 Chilean patients receiving routine endoscopy to improve the detection of early GC or preneoplastic lesions. The results showed that OLGA scores, atrophy, metaplasia and GC increased significantly with age (p < 0.001). Conversely, H. pylori infection was higher in younger groups (p < 0.05). All gastric lesions were more frequent in men than women. The majority of patients with atrophy also had metaplasia (99%, p < 0.0001). Patients with H. pylori infection had more gastric atrophy and metaplasia than those without infection (p < 0.05). Of the 485 patients, 21 (4.3%) had GC, being 2.3 times more frequent among men than women and about 2/3 (14) were in OLGA stage ≥2. In addition, 19 (90%) GC patients had atrophy and 18 (85%) had metaplasia (p < 0.001). In conclusion, the OLGA system facilitated the evaluation of GC precursor lesions particularly in patients with an OLGA score > 2 between 45 and 56 years old, because this group showed atrophy and intestinal metaplasia more frequently. Therefore, biennial endoscopic surveillance of patients with an OLGA >2 can be an important health policy in Chile for diagnosing GC in its early stages and reducing mortality over the next two decades.


The OLGA system Helicobacter pylori infection Gastric atrophy Metaplasia Gastric cancer Chilean population 



This work was supported by the DIUFRO Grant (N° DI17-0132 to MV) and The National Fund for Scientific and Technological Development (FONDECYT) Grant (N° 3170826 to IR and N° 11150802 to PB).

Compliance with Ethical Standards

Informed consent was obtained from all individual participants included in the study according to ethical requirements of WMA Declaration of Helsinki - Principles for medical research involving human subjects. We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. The funders (see Acknowledgements) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors have no conflicts of interest to declare.


  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30. CrossRefGoogle Scholar
  2. 2.
    Brenner H, Rothenbacher D, Arndt V (2009) Epidemiology of stomach cancer. Methods Mol Biol 472:467–477. CrossRefPubMedGoogle Scholar
  3. 3.
    Heise K, Bertran E, Andia ME, Ferreccio C (2009) Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol 15:1854–1862. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ferreccio C, Rollán A, Harris PR et al (2007) Gastric cancer is related to early helicobacter pylori infection in a high-prevalence country. Cancer Epidemiol Biomark Prev 16:662–667. CrossRefGoogle Scholar
  5. 5.
    Department of Statistics and Health Information. Ministry of Health. Chile
  6. 6.
    Mickevicius A, Ignatavicius P, Markelis R, Parseliunas A, Butkute D, Kiudelis M, Endzinas Z, Maleckas A, Dambrauskas Z (2014) Trends and results in treatment of gastric cancer over last two decades at single east European Centre: a cohort study. BMC Surg 14:98. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Riquelme I, Letelier P, Riffo-Campos A, Brebi P, Roa J (2016) Emerging role of miRNAs in the drug resistance of gastric Cancer. Int J Mol Sci 17:424. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    IARC (2014) Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer (IARC Working Group Reports Volume 8)Google Scholar
  9. 9.
    Lim SM, Lim JY, Cho JY (2014) Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. World J Gastroenterol 20:2042–2050. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Riquelme I, Tapia O, Leal P et al (2015) miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) 39(1):23–33. CrossRefGoogle Scholar
  11. 11.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789. CrossRefPubMedGoogle Scholar
  12. 12.
    Correa P, Piazuelo MB (2011) Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 7:59–64PubMedPubMedCentralGoogle Scholar
  13. 13.
    Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on Cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMedGoogle Scholar
  14. 14.
    Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M (2014) Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol 20:13842–13862. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB (2005) Invasive and non-invasive diagnosis of helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 40:297–301CrossRefPubMedGoogle Scholar
  16. 16.
    Rugge M (2007) Secondary prevention of gastric cancer. Gut 56:1646–1647. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhou Y, Li H-Y, Zhang J-J, Chen XY, Ge ZZ, Li XB (2016) Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol 22:3670–3678. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rugge M, Correa P, Di Mario F et al (2008) OLGA staging for gastritis: a tutorial. Dig Liver Dis 40:650–658. CrossRefPubMedGoogle Scholar
  19. 19.
    Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, de Pretis G, Graham DY (2007) Gastritis staging in clinical practice: the OLGA staging system. Gut 56:631–636. CrossRefPubMedGoogle Scholar
  20. 20.
    Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRefGoogle Scholar
  21. 21.
    Rugge M, Genta RM (2005) Staging and grading of chronic gastritis. Hum Pathol 36:228–233. CrossRefPubMedGoogle Scholar
  22. 22.
    Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M (2004) Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109:138–143. CrossRefPubMedGoogle Scholar
  23. 23.
    Cho S-J, Choi IJ, Kook M-C, Nam BH, Kim CG, Lee JY, Ryu KW, Kim YW (2013) Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther 38:1292–1302. CrossRefPubMedGoogle Scholar
  24. 24.
    Nam JH, Choi IJ, Kook M-C, Lee JY, Cho SJ, Nam SY, Kim CG (2014) OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. Helicobacter 19:81–89. CrossRefPubMedGoogle Scholar
  25. 25.
    Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, Sugano K (2008) Assessment of atrophic gastritis using the OLGA system. Helicobacter 13:225–229. CrossRefPubMedGoogle Scholar
  26. 26.
    Capelle LG, de Vries AC, Haringsma J, ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NCT, Kuipers EJ (2010) The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71:1150–1158. CrossRefPubMedGoogle Scholar
  27. 27.
    Ricci C, Holton J, Vaira D et al (2007) Diagnosis of helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol 21:299–313. CrossRefPubMedGoogle Scholar
  28. 28.
    Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P (2006) Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol 12:7172–7178. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Namekata T, Miki K, Kimmey M et al (2000) Chronic atrophic gastritis and helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol 151(8):820–830CrossRefPubMedGoogle Scholar
  30. 30.
    Correa P, Haenszel W, Cuello C et al (1975) A model for gastric cancer epidemiology. Lancet 306:58–60. CrossRefGoogle Scholar
  31. 31.
    Tatsuta M, Iishi H, Nakaizumi A, Okuda S, Taniguchi H, Hiyama T, Tsukuma A, Oshima A (1993) Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 53:70–74. CrossRefPubMedGoogle Scholar
  32. 32.
    Sipponen P, Graham DY (2007) Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 42:2–10. CrossRefPubMedGoogle Scholar
  33. 33.
    Graham DY, Nurgalieva ZZ, El-Zimaity HMT et al (2006) Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 4:306–314. CrossRefPubMedGoogle Scholar
  34. 34.
    Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, Tompkins D, Axon A (2006) Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 55:1545–1552. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  1. 1.Department of Pathological Anatomy, School of MedicineUniversidad de La FronteraTemucoChile
  2. 2.Instituto de Patología Celular y MolecularTemucoChile
  3. 3.Instituto de Ciencias Biomédicas, Facultad de Ciencias de la SaludUniversidad Autónoma de ChileTemucoChile
  4. 4.Centro de Excelencia de Modelación y Computación CientíficaUniversidad de La FronteraTemucoChile
  5. 5.GastroenterologistSantiagoChile
  6. 6.School of Medicine, Pontificia Universidad Católica de ChileSantiagoChile
  7. 7.Advanced Center for Chronic Diseases (ACCDiS), FONDAPSantiagoChile
  8. 8.Laboratory of Molecular Pathology, Department of Pathological Anatomy, School of Medicine, Center of Excellence in Translational Medicine - Scientific and Technological Bioresource Nucleus (CEMT-BIOREN)Universidad de La FronteraTemucoChile
  9. 9.Department of Public Health, School of MedicineUniversidad de La FronteraTemucoChile

Personalised recommendations